[Skip to Content]
[Skip to Content Landing]
July 1986

Effect of Intralesional a2-Interferon on Actinic Keratoses

Author Affiliations

From the Department of Internal Medicine, Section of Dermatology, University Medical Center, Tucson (Drs Edwards and Levine); the Department of Medicine, Division of Dermatology (Ms Weidner and Dr Piepkorn), and the Department of Pathology (Dr Piepkorn), University of Utah School of Medicine, Salt Lake City; and the Schering-Plough Corporation, Kenilworth, NJ (Dr Smiles).

Arch Dermatol. 1986;122(7):779-782. doi:10.1001/archderm.1986.01660190057016

† The effect of intralesional α2-interferon (IFN) on actinic keratoses was examined in this two-part study. In phase I, 11 of 12 lesions cleared following nine injections of IFN (5 × 105 IU per dose) compared with none of 12 keratoses injected with placebo. Smaller doses of IFN (1 × 105 IU and 1 × 104 IU per injection) produced clearing of 42% and 58% of lesions, respectively. The second phase, which was designed to investigate the optimum schedule for treatment with IFN, showed that a minimum of six injections of IFN (5 × 105 IU per injection) was necessary to clear 14 of 15 actinic keratoses. Although this mode of delivery is not practical for clinical use, intralesional α2-IFN demonstrates biologic activity against actinic keratoses.

(Arch Dermatol 1986;122:779-782)